DPP IV Inhibitors: Market Research Report

Date: January 4, 2016
Pages: 192
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D19D5B0CF74EN
Leaflet:

Download PDF Leaflet

DPP IV Inhibitors: Market Research Report
This report analyzes the worldwide markets for DPP IV Inhibitors in US$ Million. The Global market is analyzed by the following Drugs: Sitagliptin, Vildagliptin, Saxagliptin, and Other DPP-IV Inhibitors. The US market is analysed in terms of sales and number of prescriptions, by the following Drug Segments: Sitagliptin, Saxagliptin, Linagliptin, and Alogliptin. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 23 companies including many key and niche players such as -
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co, Inc.
  • Mitsubishi Tanabe Pharma Corporation
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Outlook for DPP-IV Therapies Remains Robust
Major Events in the DPP-IV Inhibitor Space

Table 1. Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date

TECOS Results Prove Superiority of Januvia among Gliptins
Huge Potential Exists for Januvia and Other DPP-4 Inhibitors

Table 2. Global DPP-4 Inhibitor Market by Top Five Drug Class (2015): Percentage Market Share Breakdown of Revenues (includes corresponding Graph/Chart)

The Diabetes Epidemic
Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market

Table 3. Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 Years to Treat Diabetes and Manage Associated Complications (includes corresponding Graph/Chart)

Overview of Drug Classes in Anti-Diabetic Drugs Category
Complicated T2DM Management Protocol and the Role of DPP-IV Inhibitors
DPP-4 Inhibitors – Complementing Existing Approaches
Rationale for Use of DPP-4 Inhibitors
Comparison of Anti-Diabetic Drug Classes by HbAC1 Reduction
Hunt for Novel Therapeutic Areas Attracts Pharma to DPP-4 Market
DPP-4 Inhibitors versus GLP-1 Receptor Agonists
Distinction between GLP-1 Receptor Agonists and DPP-4 Inhibitors
DPP-4 Inhibitors versus Sulfonylureas

2. A REVIEW OF SELECT APPROVED DRUGS, AND PIPELINE ANALYSIS

The DPP-4 Inhibitor Domain
Select Approved DPP-4 Inhibitors Available in Developed Markets
Januvia – The Leading DPP-IV Inhibitor Drug Worldwide
Galvus Sales Garner Significant Growth
A Comparison of Januvia and Galvus
Pharmacological Comparison of Sitagliptin and Vildagliptin
Januvia Franchise (Merck & Co. )

Table 4. Global Sales of Januvia (Sitagliptin) Franchise by Region (2016E, 2018E, 2020E & 2022E): Value Sales in US$ Million for US and RoW(includes corresponding Graph/Chart)

Implantable Drug Pump: Potential Threat to Januvia?
Galvus (Novartis)
Onglyza (AstraZeneca)

Table 5. Global Sales of Onglyza (Saxagliptin) Franchise by Region (2016, 2018, 2020 & 2022): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart)

Tradjenta (Boehringer Ingelheim)
TENELIA (Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Co., Ltd. )
Nesina (Takeda Pharmaceutical)
ZAFATEK (Takeda Pharmaceutical)
MARIZEV (Merck)
Pipeline Analysis
DPP-IV Inhibitor Pipeline
Dutogliptin Development Shelved

3. DIABETES INCIDENCE AND PREVALENCE

Table 6. Global Diabetes Mellitus Incidence among Ages 20-79 (2015 & 2040P): Prevalence (in Million) and Percentage Share by Geographic Region (includes corresponding Graph/Chart)
Table 7. Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2015 (includes corresponding Graph/Chart)

Diabetes Mellitus Cases Worldwide – A Demographic Analysis by Geographic Region
North America
The United States
Canada
Mexico

Table 8. Prevalence of Diabetes Mellitus in North America (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for the US, Canada and Mexico (includes corresponding Graph/Chart)

Europe

Table 9. Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region

Asia-Pacific

Table 10. Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka
Table 11. Prevalence of Diabetes Mellitus in Western Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region

South & Central America

Table 12. Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region

Rest of World

Table 13. Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region
Table 14. Prevalence of Diabetes Mellitus in The Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region

4. DPP-IV INHIBITORS – AN OVERVIEW OF THE DRUG CLASS

Physiology of Glucose Homeostasis
Glucose Homeostasis in the Fasting Stage
Glucose Homeostasis in the Fed Stage
What is DPP-4?
Introduction to DPP-4 Inhibitors
Mechanism of Action of DPP-4 Inhibitors
Schematic Representation of DPP-IV Inhibitor’ Mechanism of Action
DPP-4 Inhibitors in Combination with Other Anti-diabetic Medications
Advantages of DPP-4 Inhibitors
Type-2 Diabetes – The Most Prevalent Form of Diabetes
Bio-chemistry of T2DM

5. PRODUCT APPROVALS/INTRODUCTIONS

Mankind Pharma Launches Affordable Teneligliptin Drug
Zydus Cadila to Launch Tenglyn
Dong-A ST’s Evogliptin Drug SUGANON Receives Approval
PMDA Approves Merck’s MARIZEV (omarigliptin) for Type 2 Diabetes
Glenmark Launches Teneligliptin under Ziten and Zita Plus Brands
Takeda Launches ZAFATEK
FDA Approves Glyxambi (linagliptin) by Boehringer and Lilly
EC Approves Takeda’s Alogliptin Fixed-Dose Combination Therapies
Mitsubishi Receives Approval for Partial Change in Indication for TENELIA
CFDA Approves Takeda’s NESINA
USFDA Approves Takeda’s NESINA, KAZANO and OSENI

6. RECENT INDUSTRY ACTIVITY

FDA Issues Heart Failure Risk Warning to Saxagliptin and Alogliptin Medicines
First Real-world Evidence Hints at Greater Efficacy of SGLT2 Inhibitors
FDA Issues CRL to AstraZeneca Regarding Investigational Drug
Lupin and Boehringer Announce Co-Marketing Agreement
FDA Issues Safety Warning about DPP-4 Inhibitors
Merck’s TECOS Trial Meets Primary Endpoint
AstraZeneca Enters into Distribution Agreement with Dr. Reddy’s
AstraZeneca Files Lawsuit against Mylan for Patent Violation on Onglyza
BMS Completes Sale of Diabetes Business to AstraZeneca
Merck to Discontinue JUVISYNC Distribution to Pharmacies
Takeda and Sanofi Sign Co-Agreement to Market Alogliptin in China
Otsuka Pharmaceutical Receives Marketing Approval for Onglyza

7. FOCUS ON SELECT GLOBAL PLAYERS

AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Eli Lilly and Company (US)
Merck & Co, Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)

8. GLOBAL MARKET PERSPECTIVE

Table 15. World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 16. World Historic Review for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 17. World 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)
Table 18. World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19. World Historic Review for DPP-IV Inhibitors by Drug Class - Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 20. World 14-Year Perspective for DPP-IV Inhibitors by Drug Class - Percentage Breakdown of Dollar Sales for Sitagliptin, Vildagliptin, Saxagliptin, and Others Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
DPP-4 Inhibitors Set to Gain High Share in US Oral Anti-Diabetic Market
List of FDA-Approved DPP-4 Inhibitors in the US: 2016
Diabetes Pandemic in the US

Table 21. Prevalence of Diabetes Mellitus in the US (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group (includes corresponding Graph/Chart)

Categories in Diabetes Treatment Market

Table 22. The US Anti-Diabetic Market by Drug Class (2015): Percentage Share Breakdown of Revenues for Insulin, DPP-4 & SGLT-2 Inhibitors, GLP-1 Analogues, Glitazones, PPARs, and Biguanides (includes corresponding Graph/Chart)

Increased Diabetes Spending Favors the DPP-4 Inhibitor Market
Januvia Leads the Way, Will Continue to Maintain Dominance Through 2022

Table 23. The US DPP-4 Inhibitors Market by Leading Brands (2016): Percentage Market Share Breakdown of Revenues for Januvia, Janumet, Tradjenta, Onglyza, Janumet XR, Kombiglyze, and Others (includes corresponding Graph/Chart)

Minimal Differentiation Affects Sales of Onglyza

Table 24. The US Anti-Diabetes Drugs in terms of Total Prescriptions (2015): Percentage Share of Metformin, Sulfonylureas, and DPP-4 Inhibitors (Januvia, Onglyza, Tradjenta & Other) to the Total Non-Insulin Prescriptions (includes corresponding Graph/Chart)

FDA’s Issue of Safety Warning on DPP-4 Inhibitors – Potential Market Threat
Increasing Scrutiny of NDAs Delays Time-to- Market for New Drugs
Product Approvals
Strategic Corporate Developments
Select Key Players
B. Market Analytics

Table 25. The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 26. The US Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 27. The US Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 28. The US 7-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)
Table 29. The US Recent Past, Current and Future Analysis for DPP-IV Inhibitor Prescriptions by Drug Compound: Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs Analyzed with Number of Prescriptions in Thousands for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 30. The US 7-Year Perspective for DPP-IV Inhibitors Prescriptions by Drug Compound - Percentage Breakdown of Prescriptions for Sitagliptin, Saxagliptin, Linagliptin & Alogliptin Drugs for Years 2016 and 2022 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis

Table 31. Prevalence of Diabetes Mellitus in Canada (2013 & 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for Canada (includes corresponding Graph/Chart)

B. Market Analytics

Table 32. Canadian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 33. Canadian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Japan – An Important Market for DPP-IV Inhibitors

Table 34. Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)

Competition in the Japanese DPP-IV Inhibitor Market Heats Up
List of DPP-4 Inhibitors in the Japanese Market (2016)
Product Approvals/Launches
Select Key Players
B. Market Analytics

Table 35. Japanese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 36. Japanese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Current & Future Analysis
DPP-IV Inhibitors Available in the European Market
Prevalence of Diabetes in Europe: Aging Population Dominate

Table 37. Prevalence of Diabetes Mellitus in Europe (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region

Treatment Strategies of Type-2 Diabetes in Europe
Product Approval
B. Market Analytics

Table 38. European Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 39. European Historic Review for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 40. European 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Russia, and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

4A. FRANCE

Market Analysis

Table 41. French Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 42. French Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Boehringer Ingelheim GmbH – A Key Player
B. Market Analytics

Table 43. German Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 44. German Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 45. Italian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 46. Italian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

A. Market Analysis
Strategic Corporate Development
Astrazeneca plc. – a key player
B. Market Analytics

Table 47. The UK Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 48. The UK Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4E. RUSSIA

Market Analysis

Table 49. Russian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 50. Russian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4F. REST OF EUROPE

A. Market Analysis
Novartis Ag – A Key Switzerland-Based Player
B. Market Analytics

Table 51. Rest of European Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 52. Rest of European Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Asia-Pacific: The Fastest Growing Market for DPP-IV Inhibitors
Aging Populace – Potential Opportunities

Table 53. Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)

China & India Offer High Potential
Rising Diabetes Incidence in Asia-Pacific Offers Significant Growth Opportunities

Table 54. Prevalence of Diabetes Mellitus in South East Asia (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka
Table 55. Prevalence of Diabetes Mellitus in Western Asia-Pacific Regions (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region

Asia Suffers from Lack of Focus on Diabetes Care
Healthcare Societies and Associations Spread Awareness of Diabetes
B. Market Analytics

Table 56. Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 57. Asia-Pacific Historic Review for DPP-IV Inhibitors by Geographic Region - China, India, South Korea, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 58. Asia-Pacific 14-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for China, India, South Korea, and Rest of Asia-Pacific Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)

5A. CHINA

A. Market Analysis
Current & Future Analysis
China: A Market with Huge Untapped Potential for DPP-4 Inhibitor Drugs
Robust Growth Ahead Despite Initial Lag
Product Approval
Strategic Corporate Development
B. Market Analytics

Table 59. Chinese Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 60. Chinese Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5B. INDIA

A. Market Analysis
DPP-4 Inhibitor to Garner Increasing Share in Indian Diabetes Drugs Market
First-to-Market Advantage and Unique Strategy Keep Januvia Ahead of Competition
Diabetic Epidemic in the Country Spurs Market Growth
Product Launches
Strategic Corporate Developments
B. Market Analytics

Table 61. Indian Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 62. Indian Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5C. SOUTH KOREA

A. Market Analysis
Rising Competition in the Korean DPP-4 Inhibitor Market

Table 63. Korean DPP-4 Inhibitor Market (2009-2015): No. of DPP-4 Inhibitors on the Market during 2009, 2010, 2011, 2012, 2013, 2014 & 2015 (includes corresponding Graph/Chart)

Product Approval
B. Market Analytics

Table 64. South Korean Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 65. South Korean Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5D. REST OF ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Australia
Rising Incidence of Diabetes
B. Market Analytics

Table 66. Rest of Asia-Pacific Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 67. Rest of Asia-Pacific Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

A. Market Analysis
Current & Future Analysis
Latin America: National Diabetes Programs
A Peek at Brazilian Diabetes Market

Table 68. Prevalence of Diabetes Mellitus in South & Central America (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region

United Arab Emirates: Rising Diabetic Cases to Propel Market Demand
Key Statistics: Diabetes Prevalence in Middle East and African Regions

Table 69. Prevalence of Diabetes Mellitus in Middle East & North Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region
Table 70. Prevalence of Diabetes Mellitus in Africa (2013 & 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region

B. Market Analytics

Table 71. Rest of World Recent Past, Current and Future Analysis for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 72. Rest of World Historic Review for DPP-IV Inhibitors Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled:
The United States (3)
Japan (7)
Europe (4)
  Germany (1)
  The United Kingdom (1)
  Spain (1)
  Rest of Europe (1)
Asia-Pacific (Excluding Japan) (9)
Skip to top


Ask Your Question

DPP IV Inhibitors: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: